Cullen/Frost Bankers, Inc. Arvinas, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.83 Billion
- Q2 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Arvinas, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 870 shares of ARVN stock, worth $5,907. This represents 0.0% of its overall portfolio holdings.
Number of Shares
870
Previous 331
162.84%
Holding current value
$5,907
Previous $2,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ARVN
# of Institutions
243Shares Held
67.2MCall Options Held
2.92MPut Options Held
531K-
Vanguard Group Inc Valley Forge, PA9.39MShares$63.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$42.5 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.67MShares$24.9 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA3.3MShares$22.4 Million3.14% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.15MShares$14.6 Million0.01% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $361M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...